Ditchcarbon
  • Contact
  1. Organizations
  2. Pharmanutra
Public Profile
Pharmaceutical Preparation Manufacturing
IT
updated 2 months ago

Pharmanutra Sustainability Profile

Company website

Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.

DitchCarbon Score

How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

33

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Pharmanutra's score of 33 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.

53%

Let us know if this data was useful to you

Pharmanutra's reported carbon emissions

In 2023, Pharmanutra reported total carbon emissions of approximately 1,171,014 kg CO2e. This figure includes 229,189 kg CO2e from Scope 1 emissions, 270,515 kg CO2e from Scope 2 emissions (market-based), and significant Scope 3 emissions of 751,110 kg CO2e, primarily from business travel (684,328 kg CO2e) and employee commuting (86,782 kg CO2e). Comparatively, in 2022, the company recorded total emissions of about 199,150 kg CO2e for Scope 1 and 57,666 kg CO2e for Scope 2 (market-based), with no reported Scope 3 emissions. This indicates a substantial increase in emissions in 2023, particularly in Scope 3 categories, highlighting the need for enhanced sustainability measures. Pharmanutra has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction targets suggests a potential area for improvement in their climate strategy. The emissions data is not cascaded from any parent organization, indicating that Pharmanutra S.p.A. independently reports its carbon footprint. The company is headquartered in Italy and operates within the pharmaceutical industry, which is increasingly focusing on sustainability and carbon reduction commitments.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2020202120222023
Scope 1
92,590
000,000
000,000
000,000
Scope 2
39.72
00,000
00,000
000,000
Scope 3
-
-
-
000,000

How Carbon Intensive is Pharmanutra's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Pharmanutra's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Pharmanutra's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Pharmanutra is in IT, which has a low grid carbon intensity relative to other regions.

Pharmanutra's Scope 3 Categories Breakdown

Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 61% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 89% of Scope 3 emissions.

Top Scope 3 Categories

2023
Business Travel
89%
Employee Commuting
11%

Pharmanutra's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Pharmanutra has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Pharmanutra's Emissions with Industry Peers

Betterbeing

US
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

GNC Holdings, Inc.

US
•
Food products nec
Updated 19 days ago

Transaction Holdings

US
Updated 19 days ago

Unilever

GB
•
Food products nec
Updated 3 days ago

Haleon plc

GB
•
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated about 11 hours ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251121.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy